Business
Kura Oncology Reports First Quarter 2026 Financial Results
– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum – – Broad and rapid payer access achieved, with > 93% coverage and favorable positioning across > 12 million lives – – Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML – – $580.8 million in cash, c
About this update from Kura Oncology, Inc.
[{"type":"image","alt":"Kura Oncology, Inc.","displaySize":"","headline":null,"caption":"Kura Oncology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/8e159ab705e63b696053c85c0d94912a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IOFGB7AyVbH8Ah1e0o_Gjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8e159ab705e63b696053c85c0d94912a","width":300,"height":157},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/IOFGB7AyVbH8Ah1e0o_Gjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8e159ab705e63b696053c85c0d94912a","width":300,"height":157}},"lazy":false},{"type":"text","content":"– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization –","length":105,"tagName":"p"},{"type":"text","content":"– Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum –","length":144,"tagName":"p"},{"type":"text","content":"– Broad and rapid payer access achieved, with > 93% coverage and favorable positioning across > 12 million lives –","length":120,"tagName":"p"},{"type":"text","content":"– Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML –","length":106,"tagName":"p"},{"type":"text","content":"– $580.8 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program through first topline KOMET-017 Phase 3 results –","length":235,"tagName":"p"},{"type":"text","content":"– Management to host webcast and conference call today at 4:30 p.m. ET –","length":72,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for cancer, today reported first quarter 2026 financial results and provided a corporate update.","length":235,"tagName":"p"},{"type":"text","content":"“In its first full quarter of commercial availability, KOMZIFTI generated $5.8 million in net revenue, with early launch dynamics indicating growing physician adoption and utilization patterns based ...